What type of study is this?

This is a Observational study (also classified as: Animal Study).

September 10, 2025Journal of Experimental & Clinical Cancer ResearchOpen Access

Arginine depletion potentiates standard-of-care chemo-immunotherapy in preclinical models of high-risk neuroblastoma

View Full Paper

Ask AI

Bookmark

Authors

KHKimberley M. HanssenGerman Cancer Research Center JMJayne MurrayThe University of Sydney RPRuby PandherThe University of Sydney

Discussion

Member takes

Implication

Preclinical findings demonstrate that combining arginine-depleting therapy BCT-100 improves outcomes in neuroblastoma, highlighting potential new treatment strategies.

Key Points

Depletion of arginine by BCT-100 significantly delayed tumor progression in neuroblastoma models.
In vivo, tumor latency exceeded 100 days with BCT-100 plus standard-of-care therapies, compared to 45.5 days without.
BCT-100 validated in multiple models including Th-MYCN transgenic mice and patient-derived xenografts.
No increased toxicity was observed when BCT-100 was added to existing neuroblastoma treatments.

Cite This Study

Hanssen et al. (2025) studied this question.

synapsesocial.com/papers/68c1c23554b1d3bfb60efb5b https://doi.org/10.1186/s13046-025-03502-8

View Full Paper

Ask AI

Bookmark

Implication

Preclinical findings demonstrate that combining arginine-depleting therapy BCT-100 improves outcomes in neuroblastoma, highlighting potential new treatment strategies.